Chalcogen Or Nitrogen Bonded Directly To The Imidazole Ring By Nonionic Bonding Patents (Class 514/398)
-
Patent number: 8288426Abstract: A composition comprising fenamidone (a) and an insecticide compound (b) in a (a)/(b) weight ratio of from 1/1000 to 1000/1. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the pests and diseases of crops by using this composition.Type: GrantFiled: December 21, 2007Date of Patent: October 16, 2012Assignee: Bayer CropScience AGInventors: Heike Hungenberg, Wolfgang Thielert, Koen Van Den Eynde
-
Publication number: 20120245211Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed.Type: ApplicationFiled: January 11, 2012Publication date: September 27, 2012Applicants: Children's Hospital Medical Center, University of CincinnatiInventors: Joseph F. Clark, Antonius J. de Grauw
-
Publication number: 20120245132Abstract: The present invention relates to the use of low content of benzoic acid and/or sodium salt thereof in combination with one or more organic acid preservatives as active ingredients in the manufacture of a vaginal composition, wherein the composition has weak inhibition effect on normal vaginal lactobacilli while has strong inhibition effect on vaginal fungi and/or pathogenic vaginal lactobacilli, the organic acid preservatives are selected from the group consisting of dehydroacetic acid and/or sodium salt thereof, propionic acid and/or a salt thereof, sorbic acid and/or a salt thereof. The composition of the present invention is particularly useful in inhibiting vaginal fungi, and/or inhibiting pathogenic vaginal lactobacilli, and/or promoting normal vaginal lactobacilli, and/or maintaining normal vaginal acidity, and/or modulating vaginal microecosystem, and/or modulating vaginal microbials, and/or selectively decontaminating vagina.Type: ApplicationFiled: October 8, 2010Publication date: September 27, 2012Inventors: Zhongming Zeng, Ruyun Zhou
-
Patent number: 8258165Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.Type: GrantFiled: April 16, 2008Date of Patent: September 4, 2012Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Patent number: 8258164Abstract: An aqueous nitroimidazole composition comprises metronidazole, tinidazole or a combination thereof at a concentration greater than the solubility of the free base form of the nitroimidazole in water at 20° C., and a nitroimidazole crystallization-inhibiting amount of at least one organic acid. The organic acid preferably is a lower alkyl carboxylic acid (e.g., acetic acid), a polybasic acid (e.g., citric acid, tartaric acid, malic acid, polyacrylic acid, and the like), or a combination thereof. The composition can further include a thickening agent, to form a gel. The composition is free from organic co-solvents, water-soluble vitamins, and cyclodextrins; and free from nitroimidazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described.Type: GrantFiled: September 12, 2006Date of Patent: September 4, 2012Assignee: Curatek Pharmaceuticals Holding, Inc.Inventors: Robert J. Borgman, James E. Juul
-
Patent number: 8258166Abstract: A Cancer radiotherapeutic method using 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole (compound (i), and creatinine in an amount of 0.001 to part by mass with respect to 1 part by mass of compound (1); and irradiation.Type: GrantFiled: February 3, 2012Date of Patent: September 4, 2012Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Publication number: 20120220463Abstract: The present invention relates to crystalline complexes of 4-hydroxy benzoic acid and selected pesticides. It also relates to agriculturally useful compositions of the complexes.Type: ApplicationFiled: October 28, 2010Publication date: August 30, 2012Applicant: BASF SEInventors: Heidi Emilia Saxell, Rafel Israels, Ansgar Schaefer, Matthias Bratz, Hans Wolfgang Hoeffken, Ingo Brode, Elisa Nauha, Maija Nissinen
-
Patent number: 8252831Abstract: The present invention provides compounds of the formula below or pharmaceutical salts thereof, wherein R1, R2 and R3 are as described herein; methods of treating osteoarthritis using the compounds; and a process for preparing the compounds.Type: GrantFiled: December 16, 2011Date of Patent: August 28, 2012Assignee: Eli Lilly and CompanyInventors: Steven Lee Kuklish, Matthew Allen Schiffler, Jeremy Schulenburg York
-
Publication number: 20120213772Abstract: The invention provides for a method for identifying a biomarker in a fecal sample of a subject in need of such identification comprising: determining whether a fecal sample collected from a subject comprises a biomarker.Type: ApplicationFiled: January 13, 2012Publication date: August 23, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Janet R. Jansson, Benjamin Willing, Phillippe Schmitt-Kopplin, Agnes Fekete, Marianna Lucio
-
Publication number: 20120207823Abstract: Vaginal use compositions comprising pellets prepared from a debranched starch. Pellets may be conveniently prepared via extrusion/spheronization.Type: ApplicationFiled: April 24, 2012Publication date: August 16, 2012Inventors: Jean Paul Remon, Chris Vervaet, Paul Foreman
-
Publication number: 20120207822Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.Type: ApplicationFiled: February 1, 2012Publication date: August 16, 2012Inventors: Stanley Hazen, Zeneng Wang
-
Publication number: 20120202854Abstract: Compounds of formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.Type: ApplicationFiled: April 17, 2012Publication date: August 9, 2012Applicant: ARRAY BIOPHARMA INC.Inventors: George Doherty, Adam Cook
-
Publication number: 20120202756Abstract: The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.Type: ApplicationFiled: October 5, 2011Publication date: August 9, 2012Inventors: Richard Franklin, Martin Quibell, Robert G. Tyson, Bernard T. Golding
-
Publication number: 20120202738Abstract: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent.Type: ApplicationFiled: October 22, 2010Publication date: August 9, 2012Inventor: Thomas Julius Borody
-
Patent number: 8236843Abstract: Biphenyl compounds of Formula (I) and Formula (II), and their pharmaceutically acceptable salts or solvates or prodrugs, their pharmaceutical compositions, their use and process of preparation are provided. Compounds of Formula (I) and Formula (II) are disclosed to exhibit anti-inflammatory properties.Type: GrantFiled: August 24, 2009Date of Patent: August 7, 2012Assignee: Elder Pharmaceuticals Ltd.Inventors: Rajiv R. Sakhardande, Vithal Kulkarni, Nilesh Wagh, Manmohan Nimbalkar, Suhas M. Nadkarni
-
Publication number: 20120196884Abstract: The present invention relates to sulphonamide derivatives, whith a urea moiety. The invention also relates to the use of the derivatives as inhibitors of collagen receptor integrins, especially ?2?1 integrin inhibitors e.g. in connection with diseases and medical conditions that involve the action of cells and platelets expressing collagen receptors, their use as a medicament, e.g. for the treatment of thrombosis, inflammation, cancer and vascular diseases, pharmaceutical compositions containing them and a process for preparing them. The sulphonamide derivatives have the general formula (I) or (I?).Type: ApplicationFiled: June 14, 2010Publication date: August 2, 2012Applicant: BIOTIE THERAPIES CORPORATIONInventors: Jarkko Tapani Koivunen, Jani Korhonen, Anne Marjamäki, Liisa Nissinen, Marjo Pihlavisto, Olli Taneli Pentikäinen
-
Patent number: 8232306Abstract: The invention relates to methods for detecting the presence of a compound of formula I in a biological test sample: where R2, R3, and R4 are as defined in the specification; or a salt thereof.Type: GrantFiled: October 15, 2009Date of Patent: July 31, 2012Assignee: Theravance, Inc.Inventors: Yuqin Dai, Donavon McConn, Huiyu Zhou
-
Publication number: 20120189711Abstract: Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.Type: ApplicationFiled: January 9, 2012Publication date: July 26, 2012Applicant: Somerset Group Enterprises, Inc.Inventors: David G. Greenberg, Scott Puritz, Tatiana Koutchma, Juan N. Walterspiel
-
Patent number: 8217123Abstract: Disclosed are water soluble polymeric reagents comprising the structure POLY-[Y—S—W]x, where POLY is a water soluble polymer; Y is a hydrocarbon-based spacer group, x is 1 to 25, and S—W is a thiol, protected thiol, or thiol-reactive derivative. Preferably, the water soluble polymer is a PEG polymer. Also disclosed are conjugates of such polymeric reagents with pharmaceutically relevant molecules, and methods of their formation and use.Type: GrantFiled: November 10, 2010Date of Patent: July 10, 2012Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Samuel P. McManus
-
Patent number: 8216971Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.Type: GrantFiled: December 21, 2007Date of Patent: July 10, 2012Assignee: Bayer Intellectual Property GmbHInventors: Koen van Den Eynde, Wolfgang Thielert, Heike Hungenberg
-
Publication number: 20120172356Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.Type: ApplicationFiled: October 25, 2011Publication date: July 5, 2012Applicant: MCGILL UNIVERSITYInventors: Momar NDAO, Brian WARD, Hongshan LI, Vladimir PODUST, Rebecca CAFFREY, Terrance William SPITHILL, Regis PERICHON
-
Publication number: 20120165381Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: March 6, 2012Publication date: June 28, 2012Applicant: THERAVANCE, INC.Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
-
Publication number: 20120156244Abstract: Pharmaceutical compositions for the treatment of nasal congestion, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective ?-2 adrenergic receptor agonists. Methods of using the compositions for the treatment of nasal congestion, cerebrovascular disease or systemic conditions, and as delivery vehicles to deliver other active agents to treat systemic or cerebrovascular diseases or conditions.Type: ApplicationFiled: February 27, 2012Publication date: June 21, 2012Applicant: ALPHA SYNERGY DEVELOPMENT INC.Inventor: Gerald Horn
-
Publication number: 20120157506Abstract: The present invention provides compounds of the formula below or pharmaceutical salts thereof, wherein R1, R2 and R3 are as described herein; methods of treating osteoarthritis using the compounds; and a process for preparing the compounds.Type: ApplicationFiled: December 16, 2011Publication date: June 21, 2012Applicant: ELI LILLY AND COMPANYInventors: Steven Lee Kuklish, Matthew Allen Schiffler, Jeremy Schulenburg York
-
Publication number: 20120157397Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.Type: ApplicationFiled: November 28, 2011Publication date: June 21, 2012Inventors: Stanley L. Hazen, Zeneng Wang, Bruce S. Levison
-
Patent number: 8202898Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.Type: GrantFiled: February 3, 2012Date of Patent: June 19, 2012Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Publication number: 20120141574Abstract: A palatable, edible soft chewable medication vehicle for delivery of a pharmaceutically acceptable active ingredient, such as a drug, to an animal or human subject. The edible soft chews contain only food grade or better inactive ingredients, and preferably do not contain ingredients of animal origin. Processes for manufacturing the edible soft chews do not require the use of heat or the addition of water during mixing of active and inactive ingredients, provide stable concentrations of the active ingredient, and produce chews of consistent weight and texture.Type: ApplicationFiled: February 14, 2012Publication date: June 7, 2012Inventors: Neil E. Paulsen, Roland Johnson, Michael Coffee
-
Patent number: 8193234Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: GrantFiled: September 3, 2009Date of Patent: June 5, 2012Assignee: Ardea Biosciences, Inc.Inventors: Esmir Gunic, Jean-Luc Girardet, David A. Paisner
-
Publication number: 20120135929Abstract: Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, a compound disclosed herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: ApplicationFiled: May 20, 2010Publication date: May 31, 2012Applicant: Ardea Biosciences Inc.Inventors: Martha De La Rosa, Jean-Luc Girardet, Karen Watson
-
Publication number: 20120129905Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.Type: ApplicationFiled: January 31, 2012Publication date: May 24, 2012Applicant: POLA PHARMA INC.Inventors: Yasushi MURAKAMI, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Publication number: 20120122780Abstract: Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: ApplicationFiled: May 20, 2010Publication date: May 17, 2012Applicant: Ardea Biosciences Inc.Inventors: Martha De La Rosa, Jean-Luc Girardet
-
Publication number: 20120115920Abstract: The invention provides crystalline salt forms of 4?-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]-imidazol-1-ylmethyl}-3?-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compounds, processes and intermediates for preparing the crystalline compounds, and methods of using the crystalline compounds to treat diseases such as hypertension.Type: ApplicationFiled: November 9, 2011Publication date: May 10, 2012Applicant: THERAVANCE, INC.Inventors: Paul R. FATHEREE, Venkat R. THALLADI
-
Publication number: 20120115894Abstract: The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.Type: ApplicationFiled: February 22, 2010Publication date: May 10, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Ping Liu, Robert J. DeVita, Linus S. Lin, Marc D. Chioda, Terence G Hamill, Wenping Li
-
Publication number: 20120108644Abstract: The present invention provides a composition in which a fungicidal effect against a cultivated crop infected by a plant pathogen is stable and highly active. An excellent agricultural or horticultural fungicide composition for controlling a plant pathogen is provided by using (a) at least one imidazole compound represented by formula (I): wherein R represents a C1-6 alkyl group or a C1-6 alkoxy group; and n represents an integer of 1 to 5 and (b) folpet as active ingredients; by combination as compared to a single use of each compound, and a plant pathogen is thereby controlled.Type: ApplicationFiled: July 6, 2010Publication date: May 3, 2012Applicant: ISHIHARA SANGYO KAISHA, LTD.Inventor: Koji Sugimoto
-
Publication number: 20120108560Abstract: This invention provides a single phase silicone acrylate formulation that resists phase separation and includes (A) at least one of a silicone, an acrylate, and combinations thereof. The single phase silicone acrylate formulation also includes (B) a silicone acrylate hybrid compatibilizing agent including silicone functionality and (meth)acrylate functionality and that is the reaction product of a silicon-containing pressure sensitive adhesive composition, a (meth)acrylate, and an initiator. A method of minimizing phase separation of the single phase silicone acrylate formulation includes the step of combining (A) and (B) to form the single phase silicone acrylate formulation.Type: ApplicationFiled: October 21, 2011Publication date: May 3, 2012Inventors: Chana Wilson Evans, Robert O. Huber, David P. Kanios, Gary Lee Loubert, Tiffany Anne Menjoulet, Timothy Paul Mitchell, Linda Sue Nartker, Xavier Jean-Paul Thomas
-
Publication number: 20120108527Abstract: The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need thereof, and to the use of such compositions in the treatment of bacterial conditions.Type: ApplicationFiled: November 1, 2010Publication date: May 3, 2012Inventor: Prashant Sawant
-
Patent number: 8163790Abstract: Cocrystals of metronidazole are described herein. Such cocrystals are a cocrystal of metronidazole with gentisic acid and a cocrystal of metronidazole with gallic acid. Cocrystals of imipramine hydrochloride are also described. Such cocrystals are a cocrystal of imipramine hydrochloride with (+)-camphoric acid, a cocrystal of imipramine hydrochloride with fumaric acid, and a cocrystal of imipramine hydrochloride with 1-hydroxy-2-naphthoic acid.Type: GrantFiled: December 8, 2006Date of Patent: April 24, 2012Assignee: New Form Pharmaceuticals, Inc.Inventor: Scott Lawrence Childs
-
Patent number: 8163783Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.Type: GrantFiled: April 25, 2011Date of Patent: April 24, 2012Assignee: City of HopeInventors: Yun Yen, David Horne, Yate-Ching Yuan, Bing-Sen Zhou, Angela L Perkins Harki, Leila Su
-
Publication number: 20120095047Abstract: Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or the CB2 cannabinoid receptors. One aspect discloses hetero pyrrole analogs acting as antagonists for the CB1 and/or the CB2 receptors. Another aspect discloses hetero pyrrole analogs having selectivity for the CB1 or CB2 cannabinoid receptor. Also disclosed are pharmaceutical preparations employing the disclosed analogs and methods of administering therapeutically effective amounts of the disclosed analogs to provide a physiological effect.Type: ApplicationFiled: December 22, 2011Publication date: April 19, 2012Applicant: UNIVERSITY OF CONNECTICUTInventors: Alexandros Makriyannis, Rajesh Thotapally, Venkata Kiran Rao Vemuri, Teresa Olszewska
-
Publication number: 20120088744Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.Type: ApplicationFiled: May 28, 2010Publication date: April 12, 2012Applicant: PHARNEXTInventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
-
Patent number: 8153675Abstract: The invention provides a crystalline freebase form of 4?-{2-ethoxy-4-ethyl-5-[((S) -2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3?-fluorobiphenyl-2 -carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.Type: GrantFiled: November 11, 2010Date of Patent: April 10, 2012Assignee: Theravance, Inc.Inventors: Robert S. Chao, Weijiang Zhang
-
Publication number: 20120083447Abstract: Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.Type: ApplicationFiled: April 29, 2010Publication date: April 5, 2012Applicant: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Publication number: 20120077796Abstract: The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.Type: ApplicationFiled: August 10, 2011Publication date: March 29, 2012Applicants: Abbott Laboratories, Abbott GmbH & Co. KGInventors: Frauke POHLKI, Udo Lange, Wilhelm Amberg, Michael Ochse, Berthold Behl, Charles W. Hutchins, Wilfried Hornberger, Mario Mezler, Sean Turner
-
Publication number: 20120077822Abstract: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein.Type: ApplicationFiled: January 29, 2011Publication date: March 29, 2012Inventors: Shalaby W. Shalaby, Joel T. Corbett, Jason Olbrich
-
Publication number: 20120071531Abstract: Process for the protection of fish and invertebrates and all their stages of development against or for the treatment of mycoses caused by fungi of the genera Saprolegnia, Aphanomyces, Achlyaflagellata and other species important in aquacultures by use of 2-[[[[1-[3-(1-fluoro-2-phenylethyl)oxy]phenyl]ethylidene]amino]oxy]methyl]alpha-(methoxyimino)-N-methyl-alphaE-benzeneacetamide, amisulbrom, cyazofamid, enestrobin, famoxadone, fenamidone, fluoxastrobin, orysastrobin, picoxystrobin and pyribencarb. This use leads to an inhibition or destruction of pathogenic fungi. The composition, comprising at least one fungicide selected from the abovementioned group for use in fish farming and keeping is suitable for the prophylaxis and therapy of diseases of fish in aquaculture, in breeding ponds, breeding tanks, aquariums, natural stretches of game fish waters, ponds, and marine fish farms. Addition to the water and feed and direct application are the associated use forms.Type: ApplicationFiled: November 22, 2011Publication date: March 22, 2012Applicant: Bayer CropScience AGInventors: Isolde Häuser-Hahn, Klaus Stenzel, Ulrike Wachendorff-Neumann
-
Patent number: 8133911Abstract: The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.Type: GrantFiled: October 17, 2008Date of Patent: March 13, 2012Assignee: Dompe S.p.AInventors: Alessio Moriconi, Andrea Aramini
-
Patent number: 8128906Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.Type: GrantFiled: August 11, 2010Date of Patent: March 6, 2012Assignee: Lyotropic Therapeutics, Inc.Inventor: David Anderson
-
Publication number: 20120046232Abstract: Disclosed are methods and compositions comprising mGluR modulators and procysteine drugs. The methods and compositions can be used to treat subjects with prior addiction in order to reduce drug use, drug seeking or relapse.Type: ApplicationFiled: June 22, 2011Publication date: February 23, 2012Inventors: Peter Kalivas, Khaled Moussawi, Robert Malcolm
-
Patent number: 8119679Abstract: The present invention provides a method for preparing 2,4-dinitroimidazole, wherein separation of 1,4-donitroimidazole in powder form is avoided so that it is possible to eliminate allergy problems in workers and simplify the process, thereby improving process economy.Type: GrantFiled: March 8, 2011Date of Patent: February 21, 2012Assignee: Agency for Defense DevelopmentInventors: Jin Seuk Kim, Seung Hee Kim, Jin Rae Cho, Eun Mee Goh
-
Publication number: 20120040947Abstract: The present invention relates to tetraline and indane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such tetraline and indane derivatives, and the use of such tetraline and indane derivatives for therapeutic purposes. The tetraline and indane derivatives are GlyT1 inhibitors.Type: ApplicationFiled: August 10, 2011Publication date: February 16, 2012Applicants: Abbott Laboratories, Abbott GmbH & Co. KGInventors: Frauke Pohlki, Udo Lange, Wilhelm Amberg, Michael Ochse, Berthold Behl, Charles W. Hutchins